Recent epidemiologic studies have added substantial support to the hypothesis that vitamin D deficiency modifies the risk of musculoskeletal symptoms experienced with statin use.\[[@ref1][@ref2][@ref3]\]

We\[[@ref4]\] recently reported studies in 74 men and 72 women intolerant to ≥2 statins because of myalgia, myositis, myopathy, or myonecrosis, found to be vitamin D deficient. Their statin intolerance was safely resolved in most cases (88-95%) by vitamin D supplementation (50,000-100,000 units/week).\[[@ref4]\] Backes *et al*.,\[[@ref5]\] have reported that in 34 patients intolerant to three or more statins, repletion of serum vitamin D to ≥30 ng/ml (median 44 ng/ml) allowed 18 (53%) patients to "...utilize some form of alternative or daily statin dosing or a higher dose for at least 4 months..." Plausible reasons for the difference in resolution of statin intolerance in these two reports\[[@ref4][@ref5]\] included a higher serum vitamin D on treatment in our\[[@ref4]\] versus their\[[@ref5]\] study (53-55 vs. 44 ng/ml), and our predominant use of Crestor, a well-tolerated statin,\[[@ref6]\] as the challenge statin after vitamin D repletion.

Although we have not done a formal dose-response study with vitamin D supplementation in recent report of 146 statin-intolerant patients with low serum vitamin D (\<32 ng/ml) at study entry,\[[@ref4]\] the higher the serum vitamin D *within the normal range* on vitamin D supplementation, the greater the likelihood of being able to tolerate the re-challenge statin without myalgia-myositis. On vitamin D (50,000-100,000 units/week for a median duration of 14 months), 131 of the 146 patients (88%) were free of myalgia, on the re-challenge statin, but 15 (12%) still had myalgia and could not tolerate the re-challenge statin. Comparing these two groups, there were no differences (*P* \>.05) in age, race, gender and vitamin D at pre-treatment study entry, but the myalgia-free group had higher serum vitamin D after 14 months of vitamin D supplementation (55 ± 20, median 53, vs. 42 ± 13, median 36 ng/ml, *P* = .005). Serum vitamin D also increased more in the myalgia-free than myalgia persistent group (33 ± 21, median 30, vs. 21 ± 13, median 18 ng/ml, *P* = .02). With myalgia (no vs. yes) after 14 months of vitamin D supplementation, by stepwise logistic regression, with explanatory variables such as race, sex, age and serum vitamin D at study entry, serum vitamin D at follow up, and change of serum vitamin D on treatment from baseline were significant independent predictors of statin tolerance without myalgia, *P* = .02. For each unit higher in serum vitamin D, statin tolerance increased (OR = 1.04, 95% CI, 1.007-1.078; AUC = 0.726).

Given the high likelihood of substantial placebo effect\[[@ref4][@ref7][@ref8][@ref9]\] of vitamin D supplementation in vitamin D deficient, statin-intolerant patients, we have repetitively and consistently\[[@ref4][@ref7][@ref8][@ref9]\] emphasized the importance of definitive placebo-controlled, double blind studies. Within this frame of reference, The ODYSSEY ALTERNATIVE, a randomized phase 3 trial\[[@ref10]\] is of seminal importance. Total 314 statin intolerant subjects (unable to take ≥2 statins because of muscle-related adverse events \[AES\]) first received single-blind subcutaneous and oral placebo for 4 weeks, and were removed from the subsequent study if they developed muscle-related AES on placebo.\[[@ref10]\] Continuing patients were randomized (2:2:1 ratio) to Alirocumab 75 mg every two weeks, or Ezetimibe 10 mg/day, or Atorvastatin 20 mg/day for 24 weeks.\[[@ref10]\] The Alirocumab dose was increased to 150 mg every 2 weeks at week 12 depending on week 8 LDL-C levels.\[[@ref10]\] In data presented as an American Heart Abstract in 2014,\[[@ref11]\] 6.9% of subjects were excluded in the placebo run-in, establishing a threshold (without statins) of muscle AES. As noted by Backes *et al*.,\[[@ref5]\]\"...75% of the previously intolerant patients tolerated the Atorvastatin 20 mg daily for the duration of the 24-week study period.\[[@ref11]\]\" Backes *et al*.,\[[@ref5]\] concluded that "...such results strongly highlight the subjectivity of statin intolerance and the major influence of a placebo effect in many patients." Of great importance, the preliminary data\[[@ref11]\] presented for the ODYSSEY ALTERNATIVE study, suggests that Alirocumab\[[@ref10]\] will be effective and well tolerated in patients who were statin-intolerant due to muscle AES.

Vitamin D supplementation appears to benefit a majority of statin intolerant, vitamin D deficient patients, and some of the benefit arises from placebo effect. However, statin-induced myalgia has been reported in 27% of subjects treated with statins,\[[@ref12]\] and vitamin D supplementation allows a majority of previously statin-intolerant patients to take enough statins consistently enough to reach current LDL targets.\[[@ref4]\] When the PCSK9 drugs become available, as suggested by preliminary evidence\[[@ref11]\] from ODYSSEY ALTERNATIVE (Alirocumab),\[[@ref10]\] we speculate that they will provide a paradigm shift in the treatment of statin intolerance.
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